NCT05205941View on ClinicalTrials.gov

MMV533 Plasmodium Falciparum Volunteer Infection Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
Malaria
Interventions
DRUG

MMV688533

Not exceeding 200mg

Trial Locations (1)

4006

Nucleus Network Brisbane Clinic, Brisbane

Sponsors
All Listed Sponsors
collaborator

Nucleus Network Ltd

OTHER

collaborator

Southern Star Research

INDUSTRY

lead

Medicines for Malaria Venture

OTHER